Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$0.95 USD
-0.02 (-2.15%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.96 +0.01 (0.73%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Brokerage Reports
Rigel Pharmaceuticals, Inc. [RIGL]
Reports for Purchase
Showing records 101 - 113 ( 113 total )
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reports profitable quarter on milestone recognition; entering period of slow newsflow
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rigel officially a Phase III company: AstraZeneca starts ambitious 3-pivotal-Phase III trial program
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
A value play? RIGL''s Phase III oral DMARD continues to be heavily discounted; btw, earnings
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reports 1Q10: with $200M in cash and a Phase III oral asset in RA, the real story is valuation
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Rigel conundrum: one more look at the AstraZeneca deal
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S